ReviewTherapeutic advances in medical oncology2021
Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model.
Review in Therapeutic advances in medical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Immuno-oncology in the perioperative setting: the next frontier in resectable head and neck cancers - a systematic review.BMC cancer · 2026Pooled it
- Efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy or cetuximab in the treatment of platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a meta-analysis.Frontiers in pharmacology · 2026Pooled it
- The emerging role of neoadjuvant immunotherapy in locally advanced oral squamous cell carcinoma: progress and challenges.International journal of surgery (London, England) · 2026Article
- Tsunami of approvals for immune checkpoint inhibitors in early setting of head and neck tumors.Immunotherapy · 2025Article
- Neoadjuvant Immunotherapy in Head and Neck Cancers: A Paradigm Shift in Treatment Approach.Biomedicines · 2024Review
- Comprehensive survival analysis of oral squamous cell carcinoma patients undergoing initial radical surgery.BMC oral health · 2024Article
- An AI-assisted integrated, scalable, single-cell phenomic-transcriptomic platform to elucidate intratumor heterogeneity against immune response.Bioengineering & translational medicine · 2024Article
- Anti-cancer management of head and neck cancers and oral microbiome-what can we clinically obtain?Frontiers in cellular and infection microbiology · 2024Review
- Immunotherapy in Head and Neck Cancer When, How, and Why?Biomedicines · 2022Review
- Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy.Frontiers in oncology · 2021Review
- Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer.Frontiers in oncology · 2021Review
- Epigenetic modification in radiotherapy and immunotherapy for cancers.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Squamous cell carcinoma of oral cavity (OCSCC) accounts for approximately 25% of cases of head and neck squamous cell carcinoma (HNSCC). Tobacco and alcohol consumption are the main risk factors for both cancers. Surgical resection, combined with adjuvant radiotherapy or radiochemotherapy in patients with high risk of relapse, is the key element in management in the initial stages. However, despite the availability of aggressive multidisciplinary treatments, advanced resectable OCSCC carries poor prognosis; only half of the patients are disease-free 5 years after the surgery. Immunotherapy based on the use of immune checkpoint inhibitors has been proven to be effective in a wide variety of tumours, including recurrent and metastatic HNSCC. These positive results resulted in investigations into its effectiveness in earlier stages of the disease with OCSCC emerging as an interesting research model because of the accessible location of the tumours. This article reviews the potential advantages of emerging immunotherapeutic agents [mainly monoclonal antibodies against programmed cell death-1 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.